Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
FierceBiotech21h
Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger
Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...
GlobalData on MSN3d
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Hosted on MSN13d
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
Genentech publishes REGENCY trial data in the New England Journal of Medicine
Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...
Business Wire6d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Wafaa Mamilli To Join Roche As Chief Digital Technology Officer
Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles ...
Genentech announces INAVO120 study met key secondary endpoint
Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...
Business Wire14d
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis of the Phase III INAVO120 ...
Managed Healthcare Executive6d
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...
The Atlantic2mon
Fostering Healthcare Innovation Through Policy, Partnerships, and Collaborative Action
Since its founding in San Francisco in 1976, biotechnology pioneer Genentech has helped revolutionize the way doctors treat some of the world’s most complex health challenges, including the ...